Skip to content
Screener

SG&A at other companies

Eli Lilly logo
Eli LillyLLY
$3.43B+24.6%
Pfizer logo
PfizerPFE
$3.41B-0.1%
Kura Oncology logo
Kura OncologyKURA
$31.56M+38.2%
Opko Health logo
Opko HealthOPK
$52.92M-11.2%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$352.7M-31.4%
Incyte logo
IncyteINCY
$351.74M+6.3%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$13.4B+33.0%
Enterprise value$13.28B+31.7%
P/E15.6×-1.2×
P/S5.5×+1.0×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Cost of goods sold20,65719,47040,61038,642
Research and development211,987200,356411,903412,589
Selling, general and administrative147,632134,859287,234272,042
Total operating expenses380,276354,685739,747723,273
Income from operations248,414213,576499,755400,435
Interest income14,21016,78930,33735,865
Other income (expenses), net5450273(195)

Item 1. Financial Statements.

FAQ

What is Exelixis's SG&A?
Exelixis (EXEL) reported SG&A of $147.63M in Q2 2026.
How has Exelixis's SG&A changed year-over-year?
Exelixis's SG&A increased by 9.5% year-over-year, from $134.86M to $147.63M.
What is the long-term trend for Exelixis's SG&A?
Over 4 years (2021 to 2025), Exelixis's SG&A has grown at a 6.6% compound annual growth rate (CAGR), from $401.72M to $518.73M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Exelixis's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude